secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2026-08-13T12:50:09+00:00
Accession:  0001104659-26-095512
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Q2 net loss $11.5M; Halneuron Phase 2b on track, 217 patients enrolled
------------------------------------------------------------------------------

- Net loss $11.5M ($0.34/share) vs $3.8M ($1.99/share) in Q2 2025; includes $6.7M non-cash IPR&D impairment.
- Cash $9.6M provides runway through Q4 2026 Phase 2b readout; R&D $3.2M, G&A $1.6M.
- Halneuron Phase 2b CINP trial: 217 patients enrolled, top-line results expected fall 2026; 12-week extension study started.
- SP16 granted FDA IND approval; NCI-funded study at UVA to start H2 2026.
- Appointed Iain Dukes (OrbiMed) as Scientific Advisory Board Chair; legacy antiviral partnership worth up to $100M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926095512/0001104659-26-095512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926095512/dwtx-20260813x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-095512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer